Indian Medtech Startup Sigtuple Receives U.S. FDA approval; becomes India's 1st company in this space to earn the clearance

▴ SigTuple
For all haematological disorders like blood cancers, infections, anaemia & allergies, the microscopic examination of the peripheral blood smear (PBS) is the gold standard test, but microscopy today is predominantly a manual process - necessitating a highly skilled pathologist to be present on-site.

Bangalore, October 3, 2023: SigTuple, a medtech company that develops Artificial Intelligence (AI) powered digital microscopy solutions, announced that its path-breaking device AI100 with ShonitTM (Peripheral blood smear application) has received U.S. FDA 510(k) clearance. This is the first integrated hardware and AI medical device, and the first product in AI-assisted digital microscopy from India to obtain the coveted clearance and one of the handfuls of companies in the world to obtain it. 

SigTuple’s AI100 with ShonitTM is the premier solution for AI-assisted digital pathology, wherein a physical sample is digitally imaged through a microscopic lens & the AI models extract each cell and then classify it into over 30 different cell types. The pathologists can now review the samples remotely. Further, the AI helps make the pathologist more efficient, by automating most of the review. Thus, the same pathologist can now handle a much larger number of samples than she can currently, eliminating the need for an additional manual review.

Apurv Manjrekar, Chief Product Officer - SigTuple said, “SigTuple AI100 with ShonitTM automates one of the last remaining pieces of manual processes in a clinical laboratory – that of microscopic review of blood samples to detect various diseases. AI100 with ShonitTM is the first integrated hardware and AI medical device, and the first product in AI-assisted digital microscopy from India to obtain the US FDA 510(k) clearance. Even globally, US FDA clearances for digital microscopy products are few and far between. SigTuple thus finds its place among a handful of global elites to have achieved this milestone.”

Tathagato Rai Dastidar, Founder & CEO - SigTuple said, “This is a watershed moment for us – to have the quality and efficacy of our product validated and approved by one of the most stringent medical regulatory authorities in the world. This opens multiple new doorways for us to expand internationally, and build a global medical technology company out of India. The process also gave us invaluable experience on how to navigate the regulatory pathways, and this will prove to be an asset as we take our upcoming products through the approval processes”

While AI-powered digital microscopy solutions have existed for over 15 years, the technology has barely seen any meaningful traction. The abysmal low adoption could be because of lack of localisation, unaffordable pricing & inability of the incumbent’s AI to work with variation in sample quality.  AI100 addresses each of the above points holistically and is the only digital pathology solution available, which is economical and robust enough for wide-scale adoption.

About SigTuple

SigTuple is revolutionising pathology through robotics and advanced AI. We make the life of the pathologist easier, and thereby improve patient outcomes, by automating the inefficient and error-prone manual microscopic review process for the most common tests – blood and urine microscopy. We offer a software solution. The hardware is an automated slide scanner, capable of converting any physical specimen into digital images. The AI platform analyses these images and provides clinical insights into the sample, which brings down slide review time for the pathologist, and allows her to seamlessly work remotely or collaborate with other medical experts across geographies.

Tags : #SigTuple #medtech #USA #FDA #startupindia #clearance #AI #medicaldevice #medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Tier-2 and Tier-3 Cities: India's Next Big Healthcare Growth StorySeptember 18, 2026
Why Regional Hospital Chains Are Becoming More Important in IndiaSeptember 18, 2026
The Future of Indian MedTech Exports: Can India Compete With Global Leaders?September 17, 2026
Robotic-Assisted Procedures Beyond Surgery: Where Is Automation Going Next in Healthcare?September 17, 2026
58 Students from SRM Medical College Selected for Union Government Research Programmes and Grants September 16, 2026
Handpickd Questions the Role of Science in Food with ‘Science-Less’ Newspaper CampaignSeptember 16, 2026
As Women’s Cancer Burden Rises, Integrated Care Emerges as The Next Frontier in Cancer TreatmentSeptember 16, 2026
Odia Superstar Babushaan Mohanty Inaugurates Manoj Das Library at Utkal Gaurav International SchoolSeptember 16, 2026
Yashoda Hospitals, Somajiguda Successfully Treats 10-Month-Old with Complex Heart Condition Through Staged ApproachSeptember 16, 2026
Tracky launches 16D, India's first 16-day continuous glucose monitoring system (CGM)September 16, 2026
Why Local Medical Device Manufacturing Matters for Indian HealthcareSeptember 16, 2026
Next-Generation Surgical Robots Entering the Indian Market: What It Means for Patients and ProvidersSeptember 16, 2026
ShardaCare - Healthcity Marks World Sepsis Day with Training for Over 50 NursesSeptember 15, 2026
From Empowerment to Ownership: Upasana Kamineni Konidela Calls for a BRICS Women’s Economic CorridorSeptember 15, 2026
WORLD HEART DAY 2026: Don't Miss a Beat: The Heart Attacks That Never Had to HappenSeptember 15, 2026
BL Agro Announces Investment of ₹1,500 Crore In Its Biotech-Arm Leads Genetics To Build An Integrated Dairy and Genetics EcosystemSeptember 15, 2026
Can You Have PMOS With Regular Periods? What Women Often Get WrongSeptember 15, 2026
Hospital Data Breaches in India: What Every Patient Needs to Know Right NowSeptember 15, 2026
Cybersecurity of ICUs: Protecting Connected Critical-Care Systems in Indian HospitalsSeptember 15, 2026
Fortis Hospital, Shalimar Bagh Becomes Delhi NCR’s First Multi-speciality Hospital to Launch Rezūm™ Water Vapor Therapy for Enlarged ProstateSeptember 14, 2026